RxDoctor Payments Data

Olumide Oyeyipo, MD

Internal Medicine · Cape Coral, FLNPI 1922031608

Payments from drug & device makers

$5,014in general payments, 2019–2025

Across 297 payments — averaging $16.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$812
  • AbbVie$639
  • Novo Nordisk$471
  • Amarin Pharma, Inc.$440
  • Amgen$412
  • Kowa Pharmaceuticals America, Inc.$325
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$4,989100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,014 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$263,977
Medicare patients
358
Services billed
8,366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide122$165,494
EliquisApixaban128$136,675
JardianceEmpagliflozin68$97,273
JanuviaSitagliptin Phosphate41$63,987
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$41,246
MounjaroTirzepatide37$40,337
FarxigaDapagliflozin Propanediol32$35,887
RybelsusSemaglutide16$35,855
XareltoRivaroxaban24$29,934
VascepaIcosapent Ethyl29$29,387
ProliaDenosumab16$28,225
LinzessLinaclotide23$26,989
TrulicityDulaglutide13$24,179
MyrbetriqMirabegron15$19,937
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$18,205

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$471$201,349138 claims
PfizerEliquis$225$136,675128 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$812$70,95059 claims
Lilly USA, LLCMounjaro, Trulicity$220$64,51650 claims
MerckJanuvia$217$63,98741 claims
AstraZenecaFarxiga, Symbicort$205$48,02453 claims
AbbVieLinzess, Synthroid$639$29,97868 claims
Johnson & JohnsonXarelto$273$29,93424 claims
AmgenProlia$412$28,22516 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$26$15,21413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Cape Coral

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →